Fulcrum Therapeutics (FULC) EBITDA (2020 - 2025)
Historic EBITDA for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$19.4 million.
- Fulcrum Therapeutics' EBITDA rose 723.12% to -$19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.0 million, marking a year-over-year decrease of 19301.5%. This contributed to the annual value of -$9.5 million for FY2024, which is 9021.56% up from last year.
- Fulcrum Therapeutics' EBITDA amounted to -$19.4 million in Q3 2025, which was up 723.12% from -$19.8 million recorded in Q2 2025.
- Over the past 5 years, Fulcrum Therapeutics' EBITDA peaked at $52.5 million during Q2 2024, and registered a low of -$34.0 million during Q2 2022.
- For the 5-year period, Fulcrum Therapeutics' EBITDA averaged around -$20.0 million, with its median value being -$24.1 million (2021).
- In the last 5 years, Fulcrum Therapeutics' EBITDA surged by 29233.48% in 2024 and then tumbled by 13774.86% in 2025.
- Over the past 5 years, Fulcrum Therapeutics' EBITDA (Quarter) stood at -$23.8 million in 2021, then dropped by 17.56% to -$28.0 million in 2022, then decreased by 0.07% to -$28.0 million in 2023, then skyrocketed by 39.92% to -$16.8 million in 2024, then decreased by 15.57% to -$19.4 million in 2025.
- Its last three reported values are -$19.4 million in Q3 2025, -$19.8 million for Q2 2025, and -$16.8 million during Q4 2024.